{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:00:35Z","timestamp":1774947635670,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019186","name":"HORIZON EUROPE Innovative Europe","doi-asserted-by":"publisher","award":["101095052"],"award-info":[{"award-number":["101095052"]}],"id":[{"id":"10.13039\/100019186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methotrexate (MTX) is recommended as first-line therapy in patients with rheumatoid arthritis (RA), proven to be effective, safe and inexpensive. However, a significant proportion of patients does not achieve disease remission with MTX monotherapy. Main reasons include insufficient dose up-titration to the maximal recommended oral dose or the delayed switch to a subcutaneous administration route. We hypothesise, that by dose and route optimisation, a higher proportion of patients can achieve remission. Further, exploratory biomarkers will give new insights on individual MTX metabolism and drug adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MethMax trial is a prospective, randomised, assessor-blinded, parallel-group, superiority, low-intervention trial, including 182 patients across 7 European countries. Patients with active RA, na\u00efve to biologic (except tumour necrosis factor alpha inhibitors; TNFi) or targeted synthetic antirheumatic drugs, who have been on a stable oral MTX therapy for the past 3\u00a0months are randomised in a 1:1 ratio to 25\u00a0mg MTX weekly, either administered orally or subcutaneously. Additionally, both arms receive a short-term glucocorticoid regimen with a four-week tapering and withdrawal protocol. The primary endpoint is the difference in proportion of patients achieving remission defined as the Clinical Disease Activity Index (CDAI)\u2009\u2264\u20092.8 at week 24, comparing the dose\/route optimisation and oral dose optimisation. The active study duration for each patient is 24\u00a0weeks. Study visits take place at baseline, weeks 4, 12, 16 and 24. Clinical efficacy and safety parameters are obtained at each visit. Patient-reported outcomes, exploratory biomarkers as well as medication adherence are assessed. Written consent is obtained for all participants. The study has received regulatory approval via the Clinical Trials Information System and Medicines and Healthcare products Regulatory Agency and has included the first patient in August 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The anticipated results will provide insights whether the subcutaneous administration of 25\u00a0mg MTX is advantageous in achieving CDAI remission when compared to the oral intake after 24\u00a0weeks and inform the community regarding the utility of established and newly developed biomarkers, as well as the potential impact of inadequate drug adherence.<\/jats:p>\n                    <jats:p>The MethMax study is aimed to optimise individual therapy in RA and provide more precise pharmacological MTX management recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09519-4","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:55:16Z","timestamp":1774252516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An international, multicentre, interventional, randomised, assessor-blinded trial to MAXimise the METHotrexate therapy potential in patients with active rheumatoid arthritis (MethMax trial): study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-9995","authenticated-orcid":false,"given":"Karolina","family":"Anderle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Sieghart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Durechova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Bonnay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Knevel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"Lillegraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirik Klami","family":"Kristianslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"de Geest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souzi","family":"Makri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5908-1525","authenticated-orcid":false,"given":"Helga","family":"Lechner-Radner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the SQUEEZE Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"9519_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9519_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60(8):729\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9519_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301\u20137.","journal-title":"Joint Bone Spine"},{"issue":"5","key":"9519_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/RHU.0000000000000810","volume":"25","author":"L Liu","year":"2019","unstructured":"Liu L, Liu S, Wang C, Guan W, Zhang Y, Hu W, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol. 2019;25(5):197\u2013202.","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"9519_CR5","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/rheumatology\/kez213","volume":"58","author":"V Stouten","year":"2019","unstructured":"Stouten V, Westhovens R, Pazmino S, De Cock D, der Van Elst K, Joly J, et al. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. Rheumatology. 2019;58(12):2284\u201394.","journal-title":"Rheumatology"},{"key":"9519_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/OARRR.S131668","volume":"9","author":"AE Bello","year":"2017","unstructured":"Bello AE, Perkins EL, Jay R, Efthimiou P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67\u201379.","journal-title":"Open Access Rheumatol"},{"issue":"1","key":"9519_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, K\u00e4stner P, Flaxenberg P, W\u00e4hrisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73\u201381.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"9519_CR8","doi-asserted-by":"publisher","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS One. 2019;14(9):e0221823.","journal-title":"PLoS One"},{"issue":"6","key":"9519_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","volume":"75","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Thorne JC, Pope JE, Lin D, Tin D, Boire G, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1003\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9519_CR10","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515\u2005mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9519_CR11","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645\u20138.","journal-title":"J Rheumatol"},{"issue":"10","key":"9519_CR12","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.22943","volume":"56","author":"D Aletaha","year":"2007","unstructured":"Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007;56(10):3226\u201335.","journal-title":"Arthritis Rheum"},{"issue":"9410","key":"9519_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675\u201381.","journal-title":"Lancet"},{"issue":"1","key":"9519_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26\u201337.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"9519_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2014","unstructured":"Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213\u201322.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"9519_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9519_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","volume":"82","author":"CL Krieckaert","year":"2023","unstructured":"Krieckaert CL, van Tubergen A, Gehin JE, Hern\u00e1ndez-Breijo B, Le M\u00e9l\u00e9do G, Balsa A, et al. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023;82(1):65\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9519_CR18","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.24685","volume":"60","author":"JE Baggott","year":"2009","unstructured":"Baggott JE, Morgan SL. Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum. 2009;60(8):2257\u201361.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"9519_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907\u201312.","journal-title":"J Clin Invest"},{"issue":"5 Suppl 61","key":"9519_CR20","first-page":"S24","volume":"28","author":"S Goodman","year":"2010","unstructured":"Goodman S. Measuring methotrexate polyglutamates. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S24-6.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"9519_CR21","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.3899\/jrheum.131290","volume":"41","author":"E den Boer","year":"2014","unstructured":"den Boer E, de Rotte MC, Pluijm SM, Heil SG, Hazes JM, de Jonge R. Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol. 2014;41(11):2167\u201378.","journal-title":"J Rheumatol"},{"issue":"5","key":"9519_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00115-018-0643-9","volume":"90","author":"S Unterecker","year":"2019","unstructured":"Unterecker S, Hefner G, Baumann P, Gr\u00fcnder G, Bergemann N, Clement HW, et al. Therapeutic drug monitoring in neuropsychopharmacology\u202f: summary of the consensus guidelines 2017 of the TDM task force of the AGNP. Nervenarzt. 2019;90(5):463\u201371.","journal-title":"Nervenarzt"},{"issue":"5","key":"9519_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","volume":"39","author":"C Mabilat","year":"2020","unstructured":"Mabilat C, Gros MF, Nicolau D, Mouton JW, Textoris J, Roberts JA, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol Infect Dis. 2020;39(5):791\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"9519_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","volume":"7","author":"K Papamichael","year":"2022","unstructured":"Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology & Hepatology. 2022;7(2):171\u201385.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"9519_CR25","doi-asserted-by":"publisher","first-page":"e079830","DOI":"10.1136\/bmj-2024-079830","volume":"387","author":"L Kawano-Dourado","year":"2024","unstructured":"Kawano-Dourado L, Kristianslund EK, Zeraatkar D, Jani M, Makharia G, Hazlewood G, et al. Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline. BMJ. 2024;387:e079830.","journal-title":"BMJ"},{"issue":"23","key":"9519_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, Brun MK, Sandanger \u00d8, Bj\u00f8rlykke KH, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375\u201384.","journal-title":"JAMA"},{"key":"9519_CR27","unstructured":"Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo C-F, Shin K, et al. Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial. Annals of the Rheumatic Diseases. 2024:ard-2024\u2013226350."},{"issue":"10","key":"9519_CR28","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1097\/TP.0000000000004153","volume":"106","author":"P Jaksch","year":"2022","unstructured":"Jaksch P, G\u00f6rzer I, Puchhammer-St\u00f6ckl E, Bond G. Integrated immunologic monitoring in solid organ transplantation: the road toward torque teno virus-guided immunosuppression. Transplantation. 2022;106(10):1940\u201351.","journal-title":"Transplantation"},{"issue":"7","key":"9519_CR29","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1093\/rheumatology\/keab839","volume":"61","author":"P Studenic","year":"2022","unstructured":"Studenic P, Bond G, Kerschbaumer A, B\u00e9c\u00e8de M, Pavelka K, Karateev D, et al. Torque teno virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2022;61(7):2815\u201325.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"9519_CR30","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9519_CR31","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1038\/s41467-021-26245-4","volume":"12","author":"J Brunmair","year":"2021","unstructured":"Brunmair J, Gotsmy M, Niederstaetter L, Neuditschko B, Bileck A, Slany A, et al. Finger sweat analysis enables short interval metabolic biomonitoring in humans. Nat Commun. 2021;12(1):5993.","journal-title":"Nat Commun"},{"issue":"11","key":"9519_CR32","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SM Verstappen","year":"2007","unstructured":"Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9519_CR33","first-page":"483","volume":"22","author":"MS Islam","year":"2013","unstructured":"Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua R, et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J. 2013;22(3):483\u20138.","journal-title":"Mymensingh Med J"},{"key":"9519_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1456251","volume":"11","author":"N Aksoy","year":"2024","unstructured":"Aksoy N, Ozturk N, Agh T, Kardas P. Adherence to the antirheumatic drugs: a systematic review and meta-analysis. Front Med. 2024;11:1456251.","journal-title":"Front Med"},{"key":"9519_CR35","unstructured":"Institute of Nursing Science. The Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS\u00a9)."},{"issue":"8","key":"9519_CR36","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/TP.0000000000004574","volume":"107","author":"K Denhaerynck","year":"2023","unstructured":"Denhaerynck K, Dobbels F, Ko\u0161\u0165\u00e1lov\u00e1 B, De Geest S. Psychometric properties of the BAASIS: a meta-analysis of individual participant data. Transplantation. 2023;107(8):1795\u2013809.","journal-title":"Transplantation"},{"issue":"4","key":"9519_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/cpt.2974","volume":"114","author":"RCF Hebing","year":"2023","unstructured":"Hebing RCF, Bartelink IH, Gosselt HR, Heil SG, de Rotte MCFJ, de Jong PHP, et al. Methotrexate polyglutamates exposure \u2013 response modeling in a large cohort of rheumatoid arthritis patients starting methotrexate. Clin Pharmacol Ther. 2023;114(4):893\u2013903.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9519_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/ard-2024-226350","volume":"84","author":"H Tamai","year":"2025","unstructured":"Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, et al. Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial. Ann Rheum Dis. 2025;84(1):41\u20138.","journal-title":"Ann Rheum Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09519-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09519-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:58:07Z","timestamp":1774943887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09519-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9519"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09519-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the European Medicines Agency (EMA) via CTIS and by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and local ethics committees. Details can be found in the Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave their consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}